

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **CSPC PHARMACEUTICAL GROUP LIMITED**

**石藥集團有限公司**

*(Incorporated in Hong Kong with limited liability)*

**(Stock code: 1093)**

### **VOLUNTARY ANNOUNCEMENT**

#### **“LENVATINIB MESILATE CAPSULES” OBTAINS DRUG REGISTRATION APPROVAL**

The board of directors (the “**Board**”) of CSPC Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that the “Lenvatinib Mesilate Capsules (4mg)” (the “**Product**”) developed by CSPC Ouyi Pharmaceutical Co., Ltd.\* (石藥集團歐意藥業有限公司), a subsidiary of the Group, has obtained drug registration approval granted by the National Medical Products Administration of the People’s Republic of China, and is deemed to have passed the consistency of quality and efficacy evaluation of generic drugs.

Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that can inhibit the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR) and VEGFR3 (FLT4). In addition, it can inhibit other RTKs that are implicated in angiogenesis and pathway in tumorigenesis, including fibroblast growth factor receptor (FGFR). Lenvatinib mesilate capsules are indicated for patients with unresectable hepatocellular carcinoma who have not received prior systemic therapy. It has been used for the first line treatment of middle-advanced liver cancer in China, Japan, the U.S. and other countries.

The approval of the Product will further enhance the Group’s product portfolio and contribute to the Group’s development in the field of anti-tumor.

By order of the Board  
**CSPC Pharmaceutical Group Limited**  
**Cai Dongchen**  
*Chairman*

Hong Kong, 12 January 2022

*As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Dr. LI Chunlei, Dr. WANG Qingxi, Mr. CHAK Kin Man and Dr. JIANG Hao as executive directors; and Mr. WANG Bo, Mr. CHEN Chuan, Professor WANG Hongguang, Mr. AU Chun Kwok Alan and Mr. LAW Cheuk Kin Stephen as independent non-executive directors.*

*\* For identification purpose only*